Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 1998

View Archived Issues

Megabios seeks partners for oncology programs

University of Pittsburgh researcher awarded grant to study dendritic cell use in transplantation

BTG: preliminary year-end 1998 highlights

Genta to commence phase I/IIa trial with G-3139

Interim report on phase I testing of bizelesin, a bifunctional alkylating agent

Diatide's NDA for lung cancer imaging agent receives priority review

Immunomedics and Beckman Coulter form joint venture for cancer therapeutics

FDA approves first new drug for tuberculosis in 25 years

Aviron and CSL enter collaboration for FluMist

Sibia Neurosciences initiates phase I trial with SIB-1553A

Verapamil prodrug enhances activity of cytotoxic agents in resistant cell lines

German scientists synthesize novel apoptosis-inducing agents

Progenics and Pharmacopeia to jointly discover small-molecule HIV drugs

Compounds for the treatment of HIV infection developed at Janssen

Mylan to acquire Penederm

Cathepsin B and L inhibitors claimed by Canadian researchers

Astra discloses immunomodulatory peptides for oral administration

HMR discloses preparation and use of series with MMP-inhibitory activity

Celltech scientists discover potent and selective inhibitors of protein kinases

French investigators evaluate potential cell-free antitumor vaccine

HMR withdraws cerebral metabolic enhancer from Japanese market; development in AD continues

Quadramet approved in Canada

Interference with production of virulence factors as novel antibacterial strategy

Ziagen submitted for approval in U.S. and Europe

U.K. investigators identify interesting candidate for clinical evaluation

FDA says Salix ulcerative colitis Rx approvable

Clinical trials with ImaRx ultrasound agent initiated in Japan by Yamanouchi

Phytopharm's alopecia treatment enters phase II testing

Potential use of BSH in boron neutron capture therapy evaluated in clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...